Mutual Advisors LLC Purchases 9,622 Shares of Novo Nordisk A/S (NYSE:NVO)

Mutual Advisors LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 34.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 37,849 shares of the company's stock after purchasing an additional 9,622 shares during the period. Mutual Advisors LLC's holdings in Novo Nordisk A/S were worth $2,628,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in NVO. Smart Money Group LLC lifted its stake in shares of Novo Nordisk A/S by 98.5% in the first quarter. Smart Money Group LLC now owns 11,572 shares of the company's stock valued at $804,000 after buying an additional 5,743 shares in the last quarter. Resonant Capital Advisors LLC increased its holdings in Novo Nordisk A/S by 15.3% during the 1st quarter. Resonant Capital Advisors LLC now owns 7,842 shares of the company's stock worth $554,000 after purchasing an additional 1,038 shares in the last quarter. Cannon Advisors Inc. raised its stake in shares of Novo Nordisk A/S by 5.6% in the first quarter. Cannon Advisors Inc. now owns 3,948 shares of the company's stock worth $274,000 after purchasing an additional 209 shares during the last quarter. Physician Wealth Advisors Inc. lifted its position in shares of Novo Nordisk A/S by 77.9% during the first quarter. Physician Wealth Advisors Inc. now owns 1,430 shares of the company's stock valued at $99,000 after purchasing an additional 626 shares in the last quarter. Finally, FSM Wealth Advisors LLC grew its position in Novo Nordisk A/S by 5.1% in the 1st quarter. FSM Wealth Advisors LLC now owns 5,671 shares of the company's stock worth $394,000 after purchasing an additional 277 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $0.77 during midday trading on Friday, hitting $69.05. 4,047,911 shares of the company traded hands, compared to its average volume of 7,246,407. The stock has a 50-day moving average of $69.82 and a 200-day moving average of $76.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The firm has a market cap of $308.31 billion, a P/E ratio of 20.43, a PEG ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $143.69.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NVO. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. BNP Paribas began coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.